Search

Your search keyword '"A. Prejbisz"' showing total 1,517 results

Search Constraints

Start Over You searched for: Author "A. Prejbisz" Remove constraint Author: "A. Prejbisz"
1,517 results on '"A. Prejbisz"'

Search Results

51. Prevalence of smoking and clinical characteristics in fibromuscular dysplasia. The ARCADIA-POL study

52. Renal denervation – can we press the 'ON' button again?

53. Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging

58. A practical approach to the ESC 2022 cardio-oncology guidelines. Comments by a team of experts: cardiologists and oncologists

59. Miejsce lisinoprilu w nowoczesnej kardiologii

60. May Measurement Month 2021: an analysis of blood pressure screening results from Poland

61. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

62. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

64. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma

66. Metabolic syndrome — a new definition and management guidelines

68. Risks and benefits of renal artery stenting in fibromuscular dysplasia: Lessons from the ARCADIA-POL study.

72. Pregnancy-Related Complications in Patients With Fibromuscular Dysplasia: A Report From the European/International Fibromuscular Dysplasia Registry

73. Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment

74. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension

75. Dissecting visceral fibromuscular dysplasia reveals a new vascular phenotype of the disease: a report from the ARCADIA-POL study

76. Cardiac Phenotypes in Secondary Hypertension

77. Prevalence of the metabolic syndrome in Poland based on the new 2022 definition

81. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial

87. THE EUROPEAN / INTERNATIONAL FIBROMUSCULAR DYSPLASIA REGISTRY: MAIN FINDINGS IN THE FIRST THOUSAND PATIENTS

89. DISTINCTIVE FEATURES OF PATIENTS DIAGNOSED WITH FIBROMUSCULAR DYSPLASIA (FMD) AT AN OLDER AGE: A REPORT FROM THE EUROPEAN / INTERNATIONAL FMD REGISTRY

90. GENETIC STUDY OF PHACTR1 AND FIBROMUSCULAR DYSPLASIA, META-ANALYSIS AND EFFECTS ON CLINICAL FEATURES OF PATIENTS: THE ARCADIA-POL STUDY

93. IMPACT OF FMD PATIENTS’ SYSTEMATIC AND MULTIDISCIPLINARY EVALUATION ON PATIENTS’ CLINICAL MANAGEMENT -POLISH ARCADIA-POL STUDY

94. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma

95. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action

96. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.

97. Guidelines for the management of hypertension in Poland 2024 -- the position of the Polish Society of Hypertension/Polish Cardiac Society Experts.

98. Physician-patient partnership -- can it help increase adherence to the therapeutic recommendations in cardiovascular disease?

99. Ambulatory blood pressure monitoring in treated patients with hypertension in the COVID-19 pandemic - The study of European society of hypertension (ESH ABPM COVID-19 study).

Catalog

Books, media, physical & digital resources